2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Melanoma
23
Neoplasms
19
Neoplasm Metastasis
19
Squamous Cell Carcinoma of Head and Neck
17
Lung Neoplasms
13
Skin Neoplasms
12
Recurrence
10
Head and Neck Neoplasms
10
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Carcinoma, Squamous Cell
8
Carcinoma, Basal Cell
8
Breast Neoplasms
8
Urinary Bladder Neoplasms
7
Carcinoma, Merkel Cell
7
Triple Negative Breast Neoplasms
6
Colonic Neoplasms
6
Carcinoma
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Sarcoma
5
Pancreatic Neoplasms
5
Glioblastoma
5
Stomach Neoplasms
4
Multiple Myeloma
4
Mouth Neoplasms
4
Fallopian Tube Neoplasms
4
Interventions
zenocutuzumab
2
seribantumab
2
pembrolizumab
1
patritumab
1
osimertinib
1
exemestane
1
enzalutamide
1
cemiplimab
1
Vinorelbine
1
Vascular Endothelial Growth Factor A
1
Trastuzumab
1
Paroxetine
1
Paclitaxel
1
Letrozole
1
Itraconazole
1
In Situ Hybridization, Fluorescence
1
Fulvestrant
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lethal Congenital Contracture Syndrome 2
×
cemiplimab
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled